Scarica l'app Stockscreener
4.75
5.32%
0.24
Pre-mercato:
4.85
0.10
+2.11%
Precedente Chiudi:
$4.51
Aprire:
$4.61
Volume 24 ore:
699.73K
Relative Volume:
1.10
Capitalizzazione di mercato:
$237.00M
Reddito:
-
Utile/perdita netta:
$-122.31M
Rapporto P/E:
-1.052
EPS:
-4.5151
Flusso di cassa netto:
$-110.41M
1 W Prestazione:
+0.00%
1M Prestazione:
-38.23%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.60
$4.825
Intervallo di 1 settimana:
$4.41
$4.95
Portata 52W:
$4.41
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Nome
Helus Pharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare HELP vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
4.75 | 237.00M | 0 | -122.31M | -110.41M | -4.5151 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Jefferies | Buy |
| 2025-03-13 | Iniziato | Guggenheim | Buy |
| 2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Borsa (HELP) Ultime notizie
Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data - Insider Monkey
Helus Pharma appoints Michael Cola as CEO - MSN
symbol__ Stock Quote Price and Forecast - CNN
HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill
Help stock crashes on anxiety trial results, but here’s why Jefferies sees up to 200% upside - MSN
Helus Pharma reports encouraging Phase 2 results for HLP004 anxiety treatment - MSN
Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - Bitget
Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances - TipRanks
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment - Baystreet.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Assessing Cybin (HELP) Valuation After HLP004 Phase 2 Anxiety Data Draws Fresh Attention - simplywall.st
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results - Yahoo Finance
Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact? - Yahoo Finance
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Sahm
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside - Asianet Newsable
Could Helus Pharma’s HLP004 Data Quietly Reframe Cybin’s (HELP) Interventional Psychiatry Investment Story? - simplywall.st
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
Helus Pharma’s top-line Phase II data signal detection study for HLP004 - The Pharma Letter
Jefferies reiterates Helus Pharma stock rating on anxiety data By Investing.com - Investing.com Canada
Agencia de ComunicacãoHelus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Estadão Blue Studio
Helus Pharma Stock Tumbles As Anxiety Drug Study DisappointsHelus Pharma (NASDAQ:HELP) - Benzinga
Helus Pharma (HELP) Shares Drop Despite Positive Phase 2 Trial R - GuruFocus
Helus Pharma (HELP) Reports Positive Phase 2 Study Results for A - GuruFocus
Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety - TipRanks
Helus stock falls on data for anxiety therapy (HELP:NASDAQ) - Seeking Alpha
Helus Pharma announces topline results in phase 2 signal detection study for Hlp004 in patients with generalized anxiety disorder - marketscreener.com
Helus Pharma Announces Topline Results In Phase 2 Signal Detection Study For Hlp004 In Patients With Generalized Anxiety Disorder - TradingView
Helus Pharma (HELP) Price Target Raised by HC Wainwright & Co. | - GuruFocus
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - The AI Journal
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - The Malaysian Reserve
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments - Baystreet.ca
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors - Investing.com India
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors By Investing.com - Investing.com South Africa
Helus Pharma Inc Azioni (HELP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):